GLOBAL CONSORTIUM (OTC:GCGX) POISED FOR INCREASED GROWTH IN US & CANADIAN MARKET AMID UPDATES ON THE FDA CBD TRIALS
Top Cannabis companies such as Aphria (NYSE:APHA), Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are among the most anticipated cannabis stocks to monitor during these trials, which is set to take place in April to look into how the FDA might legalize CBD-additives in food products. These four cannabis giants stand to benefit significantly from a positive out-come of the trails, which ultimately aim to loosen the constraints of adding cannabis related products to food and drinks.
Now, the FDA is in the middle of it’s first round of public CBD trials, and companies such as Global Consortium Inc. (OTC:GCGX) stand to benefit significantly from the outcome of these trials. This stands particularly true for their extensive line-up of infused edibles, oils, and infusedPETS pet food line. As it stands now, the following is a general description of the current FDA CBD trials.
1) The FDA will be holding a public hearing on May 31, 2019 to get input from the public in regulating the Hemp CBD;
2) The FDA is creating a “working group” to “explore potential pathways for dietary supplements containing CBD to be lawfully marketed.”
3) The FDA issued three more warning letters to operators whom it believes made medical statements concerning Hemp CBD products that were “egregious”.